Combo of virotherapy and radiotherapy shows early promise in patients with esophageal cancer
(American Association for Cancer Research) The experimental oncolytic adenovirus telomelysin (OBP-301) in combination with radiotherapy was safe and showed early clinical efficacy in vulnerable patients with esophageal cancer, according to results from a phase I clinical trial presented at the AACR Annual Meeting 2019, March 29-April 3.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Adenoviruses | Cancer | Cancer & Oncology | Clinical Trials | Esophagus Cancer | Virotherapy